| 2026 |
In January 2026, Biocon Biologics Ltd. is set to launch three new oncology biosimilars, bolstering its robust cancer care portfolio. The company will also outline its integration as a wholly owned subsidiary of Biocon Limited, alongside emphasising the critical role of biosimilars in enhancing access to cost-effective treatments.
|
| 2025 |
In December 2025, Biocon Limited has announced the execution of an out-licensing agreement with Ajanta Pharma Ltd for the commercialisation of its vertically integrated drug product, Semaglutide, which is indicated for enhancing glycaemic control in adults with type 2 diabetes.
In December 2025, Biocon Biologics Ltd has announced a new settlement and licence agreement with Regeneron and Bayer concerning biosimilar Aflibercept (40 mg/ml) for Europe and the rest of the world, following an earlier settlement that covered the United States and Canada.
On January 31, 2025, Biocon Ltd. announced it has completed the Rs. 555 crore (US$ 64.1 million) acquisition of a 1.5% stake in Biocon Biologics Ltd., raising its total holding to 90.2%.
On January 27, 2025, Biocon Limited, achieved an improved S&P Global ESG Score of 69 in 2024, up 6 points from 2023, placing it in the 98th percentile among global biotech peers.
|
| 2024 |
On December 11, 2024, Biocon Biologics Limited, a subsidiary of Biocon Limited, announced that it has once again been recognized as an Asia IP Elite for 2024 by IAM (Intellectual Asset Management), the world's leading Intellectual Property (IP) publication. This is the eighth consecutive year for Biocon and subsequently its subsidiary Biocon Biologics to make it to this prestigious list.
In May 2024, Biocon Limited announced the signing of an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated, complex drug product, Synthetic Liraglutide.
In March 2024, Biocon Biologics Limited, a subsidiary of Biocon Limited, entered into a strategic commercial collaboration with Eris Lifesciences to broaden patient access to its portfolio of Metabolics, Oncology, and Critical Care products across India.
|
| 2023 |
In December 2023, Biocon Biologics Ltd., inked a Distribution Agreement with Sandoz, granting exclusive rights to market and distribute "Adalimumab BS for subcutaneous injection [FKB]" in Japan.
In December 2023, Bicara Therapeutics, an associate of Biocon in the US, raised US$ 165 million co-led by Braidwell and TPG.
In September 2023, Biocon Limited announced the acquisition of a manufacturing facility of Eywa Pharma Inc.
In August 2023, Biocon Foundation and Shakti Sustainable Energy Foundation organised Cities and Climate Action Workshop.
In July 2023, Biocon Biologics Ltd (BBL) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of YESAFILI®, an aflibercept biosimilar.
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd. announced that the company has completed the integration of the acquired biosimilars business in over 70 countries in Emerging Markets effective July 1, 2023, increasing the scale and scope of its business.
Biocon Biologics Wins the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2023: Bioprocessing Excellence in South Asia Award.
|
| 2022 |
In October 2022, the prestigious US-based Science magazine named Biocon as one of the Top 10 Employers in the global biotech, pharma, and biopharma sector.
In February 2022, Biocon announced the acquisition of Viatris Inc.’s biosimilar assets for US$ 3.34 billion.
|
| 2021 |
Biocon Biologics Limited (BBL) and Serum Institute Life Sciences Private Limited (SILS) announced a strategic alliance to develop antibodies for infectious diseases such as dengue, HIV and others.
In February 2021, Biocon Biologics Ltd., a subsidiary of Biocon Ltd., partnered with The International Diabetes Federation (IDF) as the first biosimilar insulin company to promote and support IDF’s Core Mission initiative and activities
In January 2021, Biocon Biologics Ltd., a subsidiary of Biocon Ltd., received Rs. 555 crore (US$ 75 Million) capital injection from a primary equity investment firm ADQ
|
| 2020 |
In November 2020, Biocon Biologics received a US$ 150 million capital injection from Goldman Sachs
On July 13, 2020, Biocon got approval from the Drugs Controller General of India (DCGI) to launch the biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients
|
| 2019 |
With the subsidiary of China Medical System Holdings Ltd. (CMS), Biocon signed the license and supply agreement for three generic formulation products in Greater China
Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia
|
| 2018 - 2017 |
Sandoz Biosimilars collaboration signed
The U.S. FDA approves Fulphila™, co-developed by Biocon and Mylan and Therapeutic Goods Administration, Australia-approved biosimilar Insulin Glargine, Semglee™ 100 IU/mL 3 mL prefilled pen
Launched Ogrivi™, the first biosimilar of trastuzumab approved by US FDA
|
| 2016 |
The Insulin Glargine pen for people with diabetes was launched in Japan as the first biosimilar from India
|
| 2014 - 2011 |
Biocon introduced CANMAb™ - Trastuzumab for Treating Breast Cancer in India
Biocon launched INSUPen®, a convenient and affordable reusable insulin delivery device
|
| 2006 |
India’s first indigenously produced novel monoclonal antibody, Nimotuzumab, for head & neck cancer, launched
|
| 2002 |
Clinigene's clinical laboratory was the first in India to receive CAP accreditation
|
| 2000 |
Biocon commissioned its first fully automated submerged fermentation plant to produce speciality pharmaceuticals and established Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development
|
| 1997 |
Biocon spearheaded initiatives in human healthcare through a dedicated manufacturing facility
|
| 1993 |
Biocon scaled up its in-house research programme
|
| 1979 |
Biocon was the first Indian company to manufacture and export enzymes to the USA and Europe
|
| 1978 |
Biocon India was incorporated as a joint venture (JV) between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Mr Kiran Mazumdar-Shaw
|
